RxDoctor Payments Data

Joel Rosenfeld, MD

Urology · Jasper, GANPI 1417051590

Payments from drug & device makers

$5,473in general payments, 2019–2025

Across 212 payments — averaging $25.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$565
  • Boston Scientific$551
  • Endo Pharmaceuticals Inc.$443
  • Pfizer$411
  • Sumitomo Pharma America, Inc.$250
  • Bayer$248
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$5,36298%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,473 in reported general payments places this provider in the 55th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$392,785
Medicare patients
753
Services billed
14,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide43$591,673
ErleadaApalutamide11$158,722
MyrbetriqMirabegron151$124,100
OrgovyxRelugolix24$72,869
GemtesaVibegron48$47,030
Mirabegron ErMirabegron15$5,235
Tamsulosin Hcl383$4,500
Finasteride291$3,399
Estradiol45$3,024
Potassium Citrate ErPotassium Citrate19$2,412
Fesoterodine Fumarate ErFesoterodine Fumarate17$1,446
Oxybutynin Chloride ErOxybutynin Chloride58$1,288
Testosterone12$812
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen102$564
Testosterone Cypionate17$521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$565$715,773194 claims
Johnson & JohnsonErleada$85$158,72211 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$250$119,89972 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 369 urology providers in Georgia.

Other urology in Jasper

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →